+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Foot Ulcer - Pipeline Insight, 2021

  • ID: 4745365
  • Clinical Trials
  • June 2021
  • Region: Global
  • 80 pages
  • DelveInsight

FEATURED COMPANIES

  • APstem Therapeutics
  • Blue Blood Biotech
  • Cynata Therapeutics
  • Helixmith
  • RHEACELL
  • SCM Lifescience
  • MORE
This “Diabetic foot ulcer - Pipeline Insight, 2021” report provides comprehensive insights about 34+ companies and 34+ pipeline drugs in Diabetic foot ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Diabetic foot ulcer Understanding


Diabetic foot ulcer: Overview


A diabetic foot ulcer is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of diabetic foot ulcers requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.

"Diabetic foot ulcer - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic foot ulcer pipeline landscape is provided which includes the disease overview and Diabetic foot ulcer treatment guidelines. The assessment part of the report embraces, in depth Diabetic foot ulcer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic foot ulcer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic foot ulcer R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic foot ulcer.

Diabetic foot ulcer Emerging Drugs Chapters


This segment of the Diabetic foot ulcer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic foot ulcer Emerging Drugs


Galnobax: NovaLead Pharma

Galnobax is a topical gel for non-healing chronic wounds. It is a repurposed generic drug molecule, which is in Phase III clinical studies for the treatment of diabetic foot ulcer (DFU).

Nemonoxacin: TaiGen Biotechnology

Nemonoxacin is a non-fluorinated quinolone (NFQ) based bacterial topoisomerase inhibitor. The drug is in Phase II clinical developmental studies for the treatment of Diabetic foot ulcer. The drug is approved for the treatment of community-acquired pneumonia.

Diabetic foot ulcer: Therapeutic Assessment


This segment of the report provides insights about the different Diabetic foot ulcer drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Diabetic foot ulcer


There are approx. 34+ key companies which are developing the therapies for Diabetic foot ulcer. The companies which have their Diabetic foot ulcer drug candidates in the most advanced stage, i.e. Phase II include, NovaLead Pharma.

Phases


This report covers around 34+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Diabetic foot ulcer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic foot ulcer: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Diabetic foot ulcer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic foot ulcer drugs.

Diabetic foot ulcer Report Insights

  • Diabetic foot ulcer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Diabetic foot ulcer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Diabetic foot ulcer drugs?
  • How many Diabetic foot ulcer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic foot ulcer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic foot ulcer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetic foot ulcer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • NovaLead Pharma
  • Helixmith
  • ShangHai HaiHe Pharmaceutical
  • Beyond Air
  • TaiGen Biotechnology
  • RHEACELL
  • Technophage
  • Transwell Biotech
  • Roche
  • Chiesi Farmaceutici
  • Blue Blood Biotech
  • Cynata Therapeutics
  • ZZ Biotech
  • APstem Therapeutics
  • Lewis and Clark Pharmaceuticals
  • Destiny Pharma
  • SCM Lifescience

Key Products

  • Galnobax
  • VM-202
  • ON101
  • Nitric oxide
  • APZ2
  • Nemonoxacin
  • TP-102
  • TWB-103
  • Efmarodocokin alfa
  • CHF-6467
  • BB 101
  • Cymerus MSC
  • 3K3A-APC
  • AP Skin 01
  • LNC-001 therapeutics
  • XF-70
  • Mesenchymal stem cell therapy


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • APstem Therapeutics
  • Blue Blood Biotech
  • Cynata Therapeutics
  • Helixmith
  • RHEACELL
  • SCM Lifescience
  • MORE
Introduction

Executive Summary

Diabetic foot ulcer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Diabetic foot ulcer - Analytical Perspective

In-depth Commercial Assessment
  • Diabetic foot ulcer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic foot ulcer Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Galnobax: NovaLead Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Nemonoxacin: TaiGen Biotechnology
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
CHF-6467: Chiesi Farmaceutici
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical/Discovery Stage Products
  • Comparative Analysis
AP Skin 01: APstem Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Diabetic foot ulcer Key Companies

Diabetic foot ulcer Key Products

Diabetic foot ulcer- Unmet Needs

Diabetic foot ulcer- Market Drivers and Barriers

Diabetic foot ulcer- Future Perspectives and Conclusion

Diabetic foot ulcer Analyst Views

Diabetic foot ulcer Key Companies

Appendix

List of Tables
Table 1 Total Products for Diabetic foot ulcer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Diabetic foot ulcer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • APstem Therapeutics
  • Beyond Air
  • Blue Blood Biotech
  • Chiesi Farmaceutici
  • Cynata Therapeutics
  • Destiny Pharma
  • Helixmith
  • Lewis and Clark Pharmaceuticals
  • NovaLead Pharma
  • RHEACELL
  • Roche
  • SCM Lifescience
  • ShangHai HaiHe Pharmaceutical
  • TaiGen Biotechnology
  • Technophage
  • Transwell Biotech
  • ZZ Biotech
Note: Product cover images may vary from those shown
Adroll
adroll